P03-55 - Paliperidone er in an acute patient unit: A clinical profile

• Published in: European psychiatry Vol. 26; p. 1224
• Main Authors: Arques, S, Pino, M.A, Arnau, F, Rubio, T, Iranzo, C
• Format: Journal Article
• Language: English
• Published: Elsevier SAS 2011
• Subjects: Internal Medicine; Psychiatry
• ISSN: 0924-9338; 1778-3585
• DOI: 10.1016/S0924-9338(11)72929-7

Introduction The emergence of new antipsychotics, such as Paliperidone Extended Release, demands a constant effort on behalf of the clinics to outline an appropriate profile for those patients who may benefit more. Objective To collect clinical and social-demographic data to develop a profile of the patient who has used Paliperidone Extended Release in our hospitalisation unit. Method This is a naturalistic, descriptive and retrospective study; we will include 36 patients admitted to our Acute Patients Unit. The inclusion and exclusion criteria were clinical. Results A total of 44.4% were over the age of 40 years; positive symptoms (52.8%) and behavioural alterations (19.4%) prevailed; the most common diagnosis was schizophrenia (47.2%). A total of 61.1% of cases were associated with other APs, especially Injectable Risperidone Extended Release or antipsychotics with a sedation profile. A total of 83.3% did not require mechanical restraint, and 80.6% did not present side effects. The most common side effects were extrapyramidal symptoms. The mean duration of hospitalisation was 19.60 ± 12.07 days. The mean dose of Paliperidone Extended Release was 14.41 ± 4.83 mg/day. Initially, a dose of 13 ± 4.42 mg/day was used, while the maximum dose was 27 mg/day. Conclusions Our experience with Paliperidone Extended Release in the hospital scope allows us to state that it is a drug with a very positive efficacy and safety-tolerability profile. Therefore, we may consider Paliperidone Extended Release a first line antipsychotic due to its contributions in different patient elements (clinical, functionality, tolerability, etc.)